ALLO vs BMY
ALLO: Allogene Therapeutics is pioneering off-the-shelf, donor-derived CAR T cell therapies to provide more scalable and accessible cancer and autoimmune disease treatments. BMY: Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse modalities like biologics and CAR-T cell technology.
Side-by-side fundamentals
| Metric | ALLO | BMY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.86 | $60.76 | |
| Market cap as of 2026-07-23 | $637M | $124.9B | |
| P/E as of 2026-07-23 | n/a | 20.91 | |
| PEG as of 2026-07-23 | n/a | -4.29 | |
| Net margin as of 2026-07-23 | -269835.0% | +12.3% | BMY higher |
| Gross margin as of 2026-07-23 | n/a | +53.7% | |
| Operating margin as of 2026-07-23 | -274487.8% | +17.1% | BMY higher |
| ROE as of 2026-07-23 | -57.1% | +41.6% | BMY higher |
| ROA as of 2026-07-23 | -41.6% | +8.7% | BMY higher |
| Debt / equity as of 2026-07-23 | 0.00 | 2.22 | ALLO lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +1.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1.4% | |
| Dividend yield as of 2026-07-23 | n/a | +4.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | BMY higher |
| Beta as of 2026-07-23 | 0.46 | 0.23 | |
| 1-year return as of 2026-07-22 close | +40.2% | +26.5% | ALLO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.